Mexiletine

Drug Profile

Mexiletine

Alternative Names: Mexiletine hydrochloride; Mexitil; Mexitilen

Latest Information Update: 28 Oct 2009

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Class Ib antiarrhythmics; Local anaesthetics; Phenyl ethers; Propylamines; Small molecules
  • Mechanism of Action Neuromuscular blocking agents; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arrhythmias; Diabetic neuropathies
  • No development reported Peripheral nervous system diseases; Torticollis

Most Recent Events

  • 20 Oct 2003 A clinical study has been added to the pharmacokinetics section
  • 15 Dec 2000 Investigation in Torticollis in Italy (Unknown route)
  • 21 Jul 2000 Launched for Diabetic neuropathies in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top